VIDEO: ATEMPT results show T-DM1 regimen effective after 5 years
Click Here to Manage Email Alerts
Follow-up results from the ATEMPT trial showed that trastuzumab emtansine remained effective years after treatment in a subset of breast cancer patients, according to data presented at San Antonio Breast Cancer Symposium.
The randomized phase 2 trial studies the activity of adjuvant ado-trastuzumab emtansine (T-DM1) in patients with resected stage I HER-2 positive breast cancer and the rate of toxicities in T-DM1 compared with paclitaxel plus trastuzumab.
“Adjuvant T-DM1 for 1 year was associated with outstanding outcomes for patients with stage I HER2 positive breast cancers, with an invasive disease-free survival rate at 5 years of 97%, and a relapse-free interval of 98.3%,” Paolo Tarantino, MD, clinical research fellow at Dana-Farber Cancer Institute and at Harvard Medical School, told Healio. “That really shows that T-DM1 is able to prevent recurrences in most [of the] patients.”
He added that researchers also conducted correlative analysis to identify any biomarkers linked with recurrence after treatment with adjuvant T-DM1 or paclitaxel plus trastuzumab. They identified a small subset of patients with tumors that were at a significantly higher risk for recurrence compared with other patients.
According to Tarantino, another study — ATEMPT 2.0 — is underway to assess six cycles of treatment with T-DM1 followed by treatment with trastuzumab for the remainder of the year.
“Hopefully, this new trial will show that a shorter regimen of T-DM1 is equally effective but can reduce the rate of discontinuation and can reduce the rate of lab abnormalities with T-DM1,” Tarantino said.
Collapse
Click Here to Manage Email Alerts